Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 01, 2024

Safety of Alpelisib Combined With Capecitabine in Patients With HER2− Metastatic Breast Cancer

Clinical Breast Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Breast Cancer
A Phase I Trial of Alpelisib Combined with Capecitabine in Patients with HER2-negative Metastatic Breast Cancer
Clin. Breast Cancer 2024 Aug 07;[EPub Ahead of Print], DM File, Y Abdou, J Force, et al

Further Reading